Appointments at AAIPharma, NextPharma and Catalent – People on the move

By Nick Taylor

- Last updated on GMT

Related tags Chief operating officer Food and drug administration Pharmaceutical drug Pharmacology

Outsourcing-Pharma presents its latest round-up of movements in the pharmaceutical outsourcing sector, including appointments at AAIPharma, NextPharma and Catalent.

AAIPharma ​has appointed Christopher Smith​ as vice president (VP) of quality and regulatory affairs. Smith has more than 30 years experience in the pharma industry at the US Food and Drug Administration (FDA), Abbott Laboratories and Endeavor Pharmaceuticals.

Ron Collins​ is representing NextPharma​’s business development affairs in the eastern region of the US and Canada. The appointment has been made in response to rising demand for services in the region.

Catalent Pharma Solutions ​has appointed Scott Houlton​ as group president of its new development and clinical services business. Houlton was most recently chief operating officer at Aptuit and has also held positions at Quintiles and Cardinal Health.

Steven Collis​ has been appointed as executive VP of contract packaging business AmerisourceBergen​. Collis was previously president of the company’s speciality group, a position he held since 1994.

Michael Mullen​ will now lead the speciality group as chief operating officer. Before taking the post Mullen was president of distribution at the speciality group.

TGaS Advisors​, a provider of advisory services to the pharma industry, has appointed Anthony Sorce​ as VP for new business development. Sorce previously worked at Thomas Reuters Healthcare.

In addition Jeff Wojcik ​has been promoted to principal. Wojick was previously working as VP and management advisor at TGaS.

Xcelience ​has appointed Brett Truitt​ as team leader, formulation development of its pharmaceutical development services division.

Truitt has more than 10 years experience in research and formulation development at companies including Bilcare Global Clinical Supplies, Shire Laboratories, Pfizer and Proctor and Gamble.

Related topics Markets & Regulations

Related news

Show more

Follow us


View more